Shots:
- The US FDA has granted clearance to ArteraAI Breast, a digital pathology-based risk stratification tool for early-stage HR+ /HER2- breast cancer, expanding the company’s oncology AI platform beyond prostate cancer
- ArteraAI Breast uses multimodal AI combining digitized histopathology images & clinical data to generate an AI-derived risk score predicting distant metastasis risk, helping clinicians stratify pts into low & high-risk groups & support more personalized treatment decisions
- Platform integrates directly into standard pathology workflows, enabling same-day prognostic results. Data presented at the SABCS’25 highlighted its potential to help guide CT benefit assessment in select patient populations
Ref: Businesswire | Image: Artera | Press Release
Related News: Caris Launches Caris MI Clarity for AI-Powered Breast Cancer Recurrence Risk Assessment
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
